Journal
ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
Volume 29, Issue 40, Pages 60035-60053Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s11356-022-19979-1
Keywords
Reverse vaccinology; Delta variant; Chimeric vaccine; Spike protein; SARS-CoV-2
Categories
Funding
- Higher Education Commission of Pakistan
- National Research Program for Universities
Ask authors/readers for more resources
This study utilized a computational reverse vaccinology approach to construct a multi-epitope vaccine against the spike protein of the delta variant, which could induce an immune response against COVID-19 infection. Non-toxic, highly conserved, non-allergenic, and highly antigenic B-cell, HTL, and CTL epitopes were identified for the development of chimeric vaccines. In silico evaluation showed that the designed chimeric vaccine could elicit an immune response.
The ongoing COVID-19 outbreak, initially identified in Wuhan, China, has impacted people all over the globe and new variants of concern continue to threaten hundreds of thousands of people. The delta variant (first reported in India) is currently classified as one of the most contagious variants of SARS-CoV-2. It is estimated that the transmission rate of delta variant is 225% times faster than the alpha variant, and it is causing havoc worldwide (especially in the USA, UK, and South Asia). The mutations found in the spike protein of delta variant make it more infective than other variants in addition to ruining the global efficacy of available vaccines. In the current study, an in silico reverse vaccinology approach was applied for multi-epitope vaccine construction against the spike protein of delta variant, which could induce an immune response against COVID-19 infection. Non-toxic, highly conserved, non-allergenic and highly antigenic B-cell, HTL, and CTL epitopes were identified to minimize adverse effects and maximize the efficacy of chimeric vaccines that could be developed from these epitopes. Finally, V1 vaccine construct model was shortlisted and 3D modeling was performed by refinement, docking against HLAs and TLR4 protein, simulation and in silico expression. In silico evaluation showed that the designed chimeric vaccine could elicit an immune response (i.e., cell-mediated and humoral) identified through immune simulation. This study could add to the efforts of overcoming global burden of COVID-19 particularly the variants of concern.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available